NEW YORK — Tataa Biocenter said on Wednesday that it has acquired a majority stake in Swedish genetic testing provider Life Genomics.
Life Genomics, which was spun off from Gothenburg-based Tataa in 2014, offers Roche's Harmony noninvasive prenatal test (NIPT) for chromosomal abnormalities, a genetic disease carrier test, and a test for Alzheimer's disease risk. According to Tataa, Life Genomics primarily operates in Sweden but also accepts samples from around 10 other countries.
Tataa said that it has acquired all Life Genomics shares held by Bure Equity and ALMI Invest, giving it a 59 percent ownership of the firm. Financial and other terms of the transaction were not disclosed.
Tataa said that it expects synergy between its COVID-19 diagnostic and testing service, which the nucleic acid analysis company launched about a year ago, and Life Genomics' NIPT offerings.